NCT05822752 2025-08-14
LIVIGNO-1
AbbVie
Phase 2 Active not recruiting
Clinical Trials
34 trialsNCT04710641 2025-03-06
OUTREACH2
Mina Alpha Limited
Phase 2 Completed
NCT03606590 2024-11-14
Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA)
NovoCure Ltd.
Phase 2 Completed
NCT03582618 2023-01-10
CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma
TaiRx, Inc.
Phase 2 Terminated
NCT02178358 2022-02-25
A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma
Eli Lilly and Company
Phase 2 Completed
NCT01033240 2021-04-08
CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer
Daiichi Sankyo
Phase 2 Completed
NCT01915602 2021-04-08
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
Bayer
Phase 2 Completed
NCT01246986 2021-01-12
A Study of LY2157299 in Participants With Hepatocellular Carcinoma
Eli Lilly and Company
Phase 2 Completed
NCT02406508 2017-12-18
Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC
Delcath Systems Inc.
Phase 2 Withdrawn
NCT01004003 2017-10-26
Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Boehringer Ingelheim
Phase 2 Completed
NCT00855218 2017-08-18
A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).
Bayer
Phase 2 Completed
NCT02114658 2017-08-03
Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients
Bayer
Phase 2 Completed
NCT00872014 2016-04-04
A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer
Amgen
Phase 2 Completed
NCT00467025 2016-03-23
AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib
Amgen
Phase 2 Completed
NCT00987935 2016-03-10
A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients
Boehringer Ingelheim
Phase 2 Completed
NCT00618982 2015-12-24
Sorafenib Dose Escalation in Renal Cell Carcinoma
Bayer
Phase 2 Completed
NCT01232296 2015-12-04
A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment
Novartis
Phase 2 Completed
NCT00791778 2015-09-28
Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer
Bayer
Phase 2 Completed
NCT00110994 2015-06-08
Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma
Bayer
Phase 2 Completed
NCT00661375 2014-12-25
BAY43-9006 Phase II Study for Renal Cell Carcinoma
Bayer
Phase 2 Completed
NCT00661180 2014-12-23
ORACLE
Bayer
Phase 2 Completed
NCT00079612 2014-12-19
Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer
Bayer
Phase 2 Completed
NCT00678288 2014-12-11
A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer.
Bayer
Phase 2 Terminated
NCT00865709 2014-12-11
Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects
Bayer
Phase 2 Completed
NCT00108953 2014-10-31
A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma
Bayer
Phase 2 Completed
NCT00117637 2014-10-31
BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma
Bayer
Phase 2 Completed
NCT00492297 2014-10-31
A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma
Bayer
Phase 2 Completed
NCT00044512 2014-04-16
A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma
Bayer
Phase 2 Completed
NCT00943449 2014-01-16
Shelter
4SC AG
Phase 2 Completed
NCT00101400 2013-12-13
BAY43-9006 - Phase II in Advanced Breast Cancer
Bayer
Phase 2 Completed
NCT00586495 2013-12-13
Long-term Extension From RCC Phase II (11515)
Bayer
Phase 2 Completed
NCT00101413 2013-10-30
BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)
Bayer
Phase 2 Completed
NCT00110344 2013-10-11
Research Study for Patients With Metastatic Renal Cell Carcinoma
Bayer
Phase 2 Terminated
NCT01204177 2013-09-06
BASIL
Bayer
Phase 2 Completed